New cancer drug DB-1317 enters first human tests
NCT ID NCT07141706
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new drug called DB-1317 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and then expanding to see if the drug shows any signs of shrinking tumors. About 233 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DB-1317 (a drug given by IV)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. It may not shrink tumors or improve survival, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AUS01-0
RECRUITINGRandwick, New South Wales, 2031, Australia
-
AUS02-0
RECRUITINGNedlands, Western Australia, 6009, Australia
-
AUS03-0
RECRUITINGLiverpool, New South Wales, 2170, Australia
-
AUS04-0
RECRUITINGWestmead, New South Wales, 2145, Australia
-
CHN03-0
RECRUITINGZhengzhou, Henan, China
-
CHN04-0
RECRUITINGJinan, Shandong, China
-
CHN05-0
RECRUITINGHarbin, Heilongjiang, China
-
Chn01-1/Chn01-2
RECRUITINGGuangzhou, Guangdong, 510060, China
-
Site USA06-0
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
USA01-0
RECRUITINGFairfax, Virginia, 22031, United States
-
USA02-0
RECRUITINGHouston, Texas, 77030, United States
-
USA03-0
RECRUITINGSan Antonio, Texas, 78229, United States
-
USA04-0
RECRUITINGLos Angeles, California, 90025, United States
-
USA05-0
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?